1-6 of 6
Ding Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Nehal J. Lakhani, Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Timothy A. Yap, Afshin Dowlati, Robert G. Maki, Susanna Ulahannan, Filipa Lynce, Karen Kelly, Stephen Williamson, Jyoti Malhotra, Shuquan Chen, Ana Gonzalez Ortiz, Vladimir Jankovic, Anne Paccaly, Sheila Masinde, Jayakumar Mani, Israel Lowy, Giuseppe Gullo, Tasha Sims, Glenn Kroog
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5601–5611.
https://doi.org/10.1158/1078-0432.CCR-23-3883
Published: 16 December 2024
View article titled, First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Open the PDF for First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4158.
https://doi.org/10.1158/1078-0432.CCR-22-2320
Published: 15 September 2022
View article titled, Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Open the PDF for Correction: First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors in another window
Journal Articles

Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1734.
https://doi.org/10.1158/1078-0432.CCR-22-0564
Published: 14 April 2022
View article titled, Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Open the PDF for Correction: First-in-Class Anti-Immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors in another window
Journal Articles

First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 57–70.
https://doi.org/10.1158/1078-0432.CCR-21-2160
Published: 01 January 2022
View article titled, First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Open the PDF for First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Samuel A. Jacobs, James J. Lee, Thomas J. George, James L. Wade, III, Philip J. Stella, Ding Wang, Ashwin R. Sama, Fanny Piette, Katherine L. Pogue-Geile, Rim S. Kim, Patrick G. Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F. Kiesel, Jan H. Beumer, Norman Wolmark, Peter C. Lucas, Carmen J. Allegra, Ashok Srinivasan
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1612–1622.
https://doi.org/10.1158/1078-0432.CCR-20-1831
Published: 15 March 2021
View article titled, Neratinib-Plus-Cetuximab in Quadruple-WT (<em>KRAS, NRAS, BRAF, PIK3CA</em>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Open the PDF for Neratinib-Plus-Cetuximab in Quadruple-WT (<em>KRAS, NRAS, BRAF, PIK3CA</em>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

George D. Demetri, Patricia Lo Russo, Iain R.J. MacPherson, Ding Wang, Jeffrey A. Morgan, Valerie G. Brunton, Prashni Paliwal, Shruti Agrawal, Maurizio Voi, T.R. Jeffry Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6232–6240.
https://doi.org/10.1158/1078-0432.CCR-09-0224
Published: 30 September 2009
View article titled, Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data